Smith & Nephew plc (NYSE:SNN - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $28.85, but opened at $25.46. Smith & Nephew shares last traded at $25.56, with a volume of 278,573 shares traded.
Analyst Ratings Changes
SNN has been the topic of several analyst reports. StockNews.com upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Monday, August 5th. Deutsche Bank Aktiengesellschaft began coverage on shares of Smith & Nephew in a research note on Wednesday, July 24th. They issued a "buy" rating for the company. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy".
View Our Latest Analysis on SNN
Smith & Nephew Stock Down 13.0 %
The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. The company's 50-day moving average price is $30.09 and its two-hundred day moving average price is $27.78.
Institutional Investors Weigh In On Smith & Nephew
Several large investors have recently modified their holdings of the company. Lorne Steinberg Wealth Management Inc. grew its holdings in Smith & Nephew by 53.6% in the second quarter. Lorne Steinberg Wealth Management Inc. now owns 231,045 shares of the medical equipment provider's stock worth $5,725,000 after purchasing an additional 80,650 shares during the period. Clearbridge Investments LLC bought a new stake in Smith & Nephew in the first quarter worth about $2,612,000. Sanctuary Advisors LLC bought a new stake in Smith & Nephew in the second quarter worth about $627,000. Tocqueville Asset Management L.P. raised its position in Smith & Nephew by 294.9% in the first quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider's stock worth $5,692,000 after acquiring an additional 167,599 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Smith & Nephew by 355.8% in the second quarter. Bank of Montreal Can now owns 1,235,916 shares of the medical equipment provider's stock valued at $31,059,000 after purchasing an additional 964,762 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.
Smith & Nephew Company Profile
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
